Spyre Therapeutics (SYRE) CMO sells 8,333 shares, retains 313,334 options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Spyre Therapeutics, Inc. Chief Medical Officer Sheldon Sloan reported an option exercise and related share sale. Sloan exercised stock options to acquire 8,333 shares of common stock at $27.46 per share, then sold 8,333 shares in an open‑market transaction at $75.00 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025. After these transactions, Sloan continues to hold 8,333 common shares directly and 313,334 stock options exercisable for common stock, with the option award originally covering 400,000 shares and expiring on October 1, 2034.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 8,333 shares ($624,975)
Net Sell
3 txns
Insider
Sloan Sheldon
Role
Chief Medical Officer
Sold
8,333 shs ($625K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 8,333 | $0.00 | -- |
| Exercise | Common Stock | 8,333 | $27.46 | $229K |
| Sale | Common Stock | 8,333 | $75.00 | $625K |
Holdings After Transaction:
Stock Option (Right to Buy) — 313,334 shares (Direct, null);
Common Stock — 8,333 shares (Direct, null)
Footnotes (1)
- This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Key Figures
Shares sold: 8,333 shares
Sale price: $75.00 per share
Shares exercised: 8,333 shares
+3 more
6 metrics
Shares sold
8,333 shares
Common stock sold in open-market transaction at $75.00
Sale price
$75.00 per share
Price for 8,333 common shares sold
Shares exercised
8,333 shares
Common shares acquired via option exercise at $27.46
Option exercise price
$27.46 per share
Exercise price for stock options
Options remaining
313,334 options
Stock options outstanding after transaction, expiring October 1, 2034
Original option award size
400,000 shares
Total shares underlying option grant subject to vesting
Key Terms
Rule 10b5-1 trading plan, Stock Option (Right to Buy), exercise or conversion of derivative security, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an expiration date of 2034-10-01"
exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
open-market sale financial
"transaction_action: open-market sale for 8,333 common shares at $75.0000"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
vesting in monthly installments financial
"remaining three quarters vesting in monthly installments over the following three years"
FAQ
What insider transactions did Spyre Therapeutics (SYRE) report for Sheldon Sloan?
Spyre Therapeutics reported that Chief Medical Officer Sheldon Sloan exercised stock options for 8,333 common shares and sold 8,333 shares in an open-market transaction. These moves combine a derivative exercise with a matching share sale on the same date.
What options did the Spyre Therapeutics (SYRE) CMO exercise in this Form 4?
Sloan exercised stock options covering 8,333 shares of Spyre Therapeutics common stock at an exercise price of $27.46 per share. These options are part of a larger award originally representing the right to purchase 400,000 shares, subject to vesting conditions.
Does the Spyre Therapeutics (SYRE) CMO still hold options after this transaction?
Yes. After the reported transactions, Sloan holds 313,334 stock options with an exercise price of $27.46 per share. These options relate to an award expiring on October 1, 2034, and continue vesting according to the stated schedule.
Was the Spyre Therapeutics (SYRE) insider sale under a Rule 10b5-1 plan?
Yes. The Form 4 footnotes state that the reported sale was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. Such plans pre-arrange trades, helping separate routine liquidity from discretionary timing decisions.
What is the vesting schedule of the Spyre Therapeutics (SYRE) CMO’s option award?
The option award initially covered 400,000 shares of common stock. One quarter vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over three years, contingent on continued employment with Spyre Therapeutics.